SAUSALITO, Calif., April 14, 2014 /PRNewswire/ -- Sanovas Inc., a Life Sciences Accelerator developing and commercializing next-generation micro-invasive diagnostics, devices and drug delivery technologies, announced today that it has appointed Jeff Heerto serve as Chief Operating Officer.
Previously, Jeff was Vice President of Manufacturing and Customer Support at Picarro Inc., a leading provider of solutions to measure rare gases for applications across the Energy/Utility and Scientific markets; Vice President of Operations and Administration for CardioDx®, a cardiovascular genomic diagnostics company; Vice President of Operations at Peak Surgical, which was acquired by Medtronic; and Vice President of Operations for Stryker Endoscopy.
"Jeff is a highly accomplished visionary executive with domestic and international experience in vital functions including Operations, Quality, Engineering, Human Resources, Sales and Marketing in high-growth Life Science companies. His experience driving Stryker Endoscopy's surgical camera business will complement Sanovas' commercialization initiatives on behalf of our MicroCam business unit. Jeff is the perfect executive to vitalize Sanovas growth and expansion into a major global life sciences company," said Larry Gerrans, Co-Founder, President and CEO.
"Jeff's appointment as COO of Sanovas bears strong testimony to our commitment to aggressive growth," Gerrans added. "Our family of companies are creating and commercializing potentially blockbuster technologies that have a common denominator: they empower surgeons to access, image, diagnose, measure and treat diseased and obstructed passageways and anatomy in areas of the human body that have been inaccessible . . . until now."
At the heart of the Sanovas companies' scientific advances is the miniaturization of tools for minimally invasive surgery, or "M-I-S." Its products extend access beyond current limits, enabling physicians to diagnose and perform therapeutic interventions in spaces as small as one millimeter in diameter that have previously been unreachable. Sanovas expects to commercialize the technology in coordination with its various partners to address unmet clinical needs in Oncology, Pulmonology, ENT, Cardiovascular, GI, General Surgery, Urology and Gynecology.
Read more news from Sanovas.